<p>Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 获取免费报告）周二股价上涨了 12.2%。该股最高交易价为 17.13 美元，最后交易价为 17.00 美元。在午盘交易中，约有 77,154 股易手，较日均交易量 40,114 股增加了 92%。该股此前收盘价为 15.15 美元。</p>
<p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析师升级与降级</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位投资分析师对该股给予了卖出评级，根据 MarketBeat.com 的数据，Coeptis Therapeutics 目前的共识评级为 “卖出”。</p>
<p><strong>阅读我们关于 Coeptis Therapeutics 的最新股票报告</strong></p>
<h2>Coeptis Therapeutics 股价上涨 12.2%</h2>
<p>该股市值为 9078 万美元，市盈率为-5.18，贝塔值为-0.50。该公司的 50 日简单移动平均线为 15.16 美元，200 日简单移动平均线为 11.96 美元。公司的速动比率为 0.83，流动比率为 2.21，债务股本比率为 0.01。</p>
<h2>机构投资者对 Coeptis Therapeutics 的看法</h2>
<p>一家对冲基金最近在 Coeptis Therapeutics 股票中购买了新股份。Yorkville Advisors Global LP 在第三季度购买了 Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 免费报告）的新股份，根据其最近向证券交易委员会提交的 13F 文件，该基金购买了 8,000 股该公司的股票，价值约为 140,000 美元。Coeptis Therapeutics 占 Yorkville Advisors Global LP 投资组合的约 0.0%，使该股成为其第 24 大持股。截至其最近的 SEC 文件，Yorkville Advisors Global LP 持有 Coeptis Therapeutics 的 0.17%。机构投资者持有该公司 13.88% 的股票。</p>
<h2>关于 Coeptis Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症的细胞治疗，包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同的肿瘤类型，包括血液恶性肿瘤和实体肿瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Coeptis Therapeutics 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>高通的牛市正在失去犯错的空间</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
<p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Coeptis Therapeutics 并不在名单上。</p>
<p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COEP

<p>Coeptis Therapeutics（纳斯达克代码：COEP）股票上涨 12.2%，至 17.00 美元，交易量较平均水平增加 92%。尽管股价上涨，Weiss Ratings 仍重申了 “卖出” 评级。该公司市值为 9078 万美元，开发用于癌症的细胞治疗平台。机构投资者持有该股票的 13.88%。Yorkville Advisors 最近获得了新的股份。分析师建议其他股票可能是更好的投资选择</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) shares rose 12.2% on Tuesday . The stock traded as high as $17.13 and last traded at $17.00. Approximately 77,154 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 40,114 shares. The stock had previously closed at $15.15.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 获取免费报告）周二股价上涨了 12.2%。该股最高交易价为 17.13 美元，最后交易价为 17.00 美元。在午盘交易中，约有 77,154 股易手，较日均交易量 40,114 股增加了 92%。该股此前收盘价为 15.15 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics presently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位投资分析师对该股给予了卖出评级，根据 MarketBeat.com 的数据，Coeptis Therapeutics 目前的共识评级为 “卖出”。</p>
</div><p><strong>Read Our Latest Stock Report on Coeptis Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Coeptis Therapeutics 的最新股票报告</strong></p>
</div><h2>Coeptis Therapeutics Trading Up 12.2%</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股价上涨 12.2%</h2>
</div><p>The stock has a market cap of $90.78 million, a P/E ratio of -5.18 and a beta of -0.50. The firm's 50 day simple moving average is $15.16 and its two-hundred day simple moving average is $11.96. The company has a quick ratio of 0.83, a current ratio of 2.21 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>该股市值为 9078 万美元，市盈率为-5.18，贝塔值为-0.50。该公司的 50 日简单移动平均线为 15.16 美元，200 日简单移动平均线为 11.96 美元。公司的速动比率为 0.83，流动比率为 2.21，债务股本比率为 0.01。</p>
</div><h2>Institutional Investors Weigh In On Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Coeptis Therapeutics 的看法</h2>
</div><p>A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP's portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics as of its most recent SEC filing. Institutional investors own 13.88% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近在 Coeptis Therapeutics 股票中购买了新股份。Yorkville Advisors Global LP 在第三季度购买了 Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 免费报告）的新股份，根据其最近向证券交易委员会提交的 13F 文件，该基金购买了 8,000 股该公司的股票，价值约为 140,000 美元。Coeptis Therapeutics 占 Yorkville Advisors Global LP 投资组合的约 0.0%，使该股成为其第 24 大持股。截至其最近的 SEC 文件，Yorkville Advisors Global LP 持有 Coeptis Therapeutics 的 0.17%。机构投资者持有该公司 13.88% 的股票。</p>
</div><h2>About Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>关于 Coeptis Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症的细胞治疗，包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同的肿瘤类型，包括血液恶性肿瘤和实体肿瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Coeptis Therapeutics 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>高通的牛市正在失去犯错的空间</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Coeptis Therapeutics 并不在名单上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coeptis Therapeutics (NASDAQ:COEP) 股价上涨 12.2% - 接下来会如何发展？